Related Experiment Videos
Clinical application of immunosuppressive agents in renal transplantation
1Department of Internal Medicine, University of Cincinnati Medical Center, Ohio, USA.
Abstract:
The availability of a number of new immunosuppressive drugs has resulted in significant improvements in the outcome of kidney transplantation. Currently 1-year graft survival rate for cadaver kidney transplants is approximately 85%. A number of new agents are presently in clinical studies. This article reviews the currently available agents and examines various aspects of induction and maintenance immunosuppressive therapy, and the treatment of acute rejection episodes. In addition, the agents currently in clinical trials and future directions in immunosuppressive therapy are discussed.
Insights
New immunosuppressive drugs have improved kidney transplant outcomes, with a current 1-year graft survival rate of 85%. This review covers available and emerging therapies for induction, maintenance, and rejection treatment.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Significant advancements in immunosuppressive pharmacotherapy have enhanced kidney transplant success rates.
- The 1-year graft survival for cadaveric kidney transplants currently approaches 85%.
Purpose of the Study:
- To review current immunosuppressive drugs for kidney transplantation.
- To examine induction and maintenance immunosuppressive strategies.
- To discuss acute rejection treatment and future therapeutic directions.
Main Methods:
- Literature review of available and investigational immunosuppressive agents.
- Analysis of current clinical practices in immunosuppression.
- Discussion of emerging trends in transplantation therapy.
Main Results:
- New immunosuppressive agents have led to improved graft survival rates.
- Established protocols for induction, maintenance, and acute rejection management exist.
- Several novel agents are in clinical trials, indicating ongoing therapeutic development.
Conclusions:
- Current immunosuppressive therapies have markedly improved kidney transplant outcomes.
- Ongoing research and clinical trials are paving the way for future advancements in immunosuppression.
- Optimizing immunosuppressive strategies remains critical for long-term graft survival.